Navigation Links
Regado Biosciences, Inc. Announces Presentation of the Results of the RADAR Phase 2b Clinical Trial of Its Anticoagulant System REG1 at the i2 Summit During the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans
Date:3/28/2011

agulants and antiplatelet agents) in the acute and sub-acute care cardiovascular setting, a multi-billion dollar world-wide market in need of drugs with improved safety profiles and a greater degree of therapeutic control.  The products in Regado's pipeline are designed to act as optimized antithrombotics, uniquely concomitantly minimizing the risk of ischemia and bleeding, and, by allowing patient specific tuning of the desired therapeutic effect, providing a safe and unique approach to personalized medicine.

ABOUT REG1, REG2 and REG3  

Regado's lead program, the anticoagulant system REG1, consists of two parenteral agents both administered by IV bolus, the first being a potent highly selective Factor IXa inhibitor (pegnivacogin, a.k.a. RB006) and the second being its complementary active control agent (anivamersen, a.k.a. RB007).  Anivamersen can be used to selectively completely or partially reverse the anticoagulant effect of pegnivacogin.  REG1, having recently completed phase 2b clinical development (the RADAR trial), is intended for application in arterial thrombosis indications, such as Acute Coronary Syndrome patients undergoing Percutaneous Coronary Intervention.  A clinical program in Open Heart Surgery [including coronary artery bypass grafting (CABG) and valve repair/replacement] is also under development.  REG2, Regado's second product candidate, consists of a subcutaneously administered depot formulation of pegnivacogin paired with the IV bolus formulation of anivamersen.  REG2 recently completed single escalating dose phase 1 clinical testing (the first successful subcutaneous application of an aptamer in humans) and is planned to be studied in a multiple escalating dose clinical trial in 2011.  It is intended for use in venous thrombosis indications such as venous thromboembolism (VTE) prophylaxis in patients undergoing abdominal surgery.  REG3, Regado's third program, consists of a s
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Regado Biosciences to Present at the 2011 RBC Capital Markets Healthcare Conference in New York City
2. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
3. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
4. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
5. Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania
6. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
7. Regado Biosciences to Present at the Stifel Nicolaus Healthcare Conference 2010 on September 16, 2010 in Boston, Massachusetts
8. Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts
9. Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010
10. Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009
11. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... BURLINGTON, Mass. , Dec. 18, 2014  Decision ... the United States will increase ... Growth will be primarily driven by expansion in the ... direct energy devices will be increasingly adopted due to ... launched. Other key findings from Decision Resources ...
(Date:12/19/2014)... KANSAS CITY, Kan. , Dec. 18, 2014 ... PETX ), a biopharmaceutical company focused on ... for companion animals, today announced positive results from ... company,s innovative drug for treating pain in dogs ... demonstrated improvements in pain assessment scores that were ...
(Date:12/17/2014)... -- Revenue and earnings above the previous year ... In the past 2013/14 fiscal year (ended 30 ... EUR 4.287 billion (last year: EUR 4.190 billion) despite unfavorable ... 360 million. "Overall, 2013/14 was a successful fiscal year for ... and CEO of Carl Zeiss AG. "Thanks to our broad ...
Breaking Medicine Technology:U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5ZEISS Asserts its Position in Difficult Environment 2
(Date:12/19/2014)... Diet Doc strives to continue to ... weight loss by combining scientific fast weight ... the company understand that remaining committed to a diet ... carbohydrates and sugars from the diet can cause patients ... weight loss goals. , For this reason, Diet ...
(Date:12/19/2014)... December 19, 2014 B. E. Smith, ... healthcare providers, has been retained to lead a national ... Medical Center in Estes Park, Colo. The top executive ... has recently placed more than 900 healthcare executives into ... a 25-bed, not-for-profit critical access hospital and level IV ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 The ... shifting, capital equipment market that is saturated with ... safety and efficacy as well as non-invasive nature, ... were first introduced to the healthcare market. Rapid ... development of MRI safe technologies have greatly expanded ...
(Date:12/19/2014)... Hands On Mobile Spa, has announced they now have a ... been transformed into a utopia for the Long Island community ... The Virtual Tour showcases the beauty of the Spa On ... more. , The Virtual Tour shows viewers each of the ... overhauled Winnebago. Marla Kaplan-Pelle, Director states " It's hard to ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 If you ... having difficulty breathing, you probably wished you had an ... asthma, COPD, cystic fibrosis, and other breathing disorders. Currently, ... medications and avoiding triggers, but other common treatments do ... Educators conference in San Antonio, TX, 34 asthma educators ...
Breaking Medicine News(10 mins):Health News:Diet Doc Incorporates Appetite Zap into their Already Impressive Collection of Diet Products to Jump Start the Metabolism and Burn Fat 4X Faster 2Health News:Diet Doc Incorporates Appetite Zap into their Already Impressive Collection of Diet Products to Jump Start the Metabolism and Burn Fat 4X Faster 3Health News:Diet Doc Incorporates Appetite Zap into their Already Impressive Collection of Diet Products to Jump Start the Metabolism and Burn Fat 4X Faster 4Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 2Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 3Health News:Magnetic Resonance Imaging Systems Market Analysis and Forecast to 2020 Report at RnRMarketReserach.com 2Health News:Magnetic Resonance Imaging Systems Market Analysis and Forecast to 2020 Report at RnRMarketReserach.com 3Health News:Magnetic Resonance Imaging Systems Market Analysis and Forecast to 2020 Report at RnRMarketReserach.com 4Health News:A Virtual Tour Of Hands On Mobile Massage Spa Is Now Available 2Health News:A Virtual Tour Of Hands On Mobile Massage Spa Is Now Available 3Health News:Harmonica Techs, Inventors of the Pulmonica®, Unveil New Findings on Complementary Treatments for Asthma 2Health News:Harmonica Techs, Inventors of the Pulmonica®, Unveil New Findings on Complementary Treatments for Asthma 3
... in Huntingtons disease take place earlier in cell life ... Medicine in Houston in a report that appears in ... research provides evidence of toxicity by huntingtin (the protein ... said Dr. Juan Botas, associate professor of molecular and ...
... study finds, , , WEDNESDAY, Jan. 9 (HealthDay News) -- It ... such as schizophrenia and bipolar disorder, very early in the ... five factors that were often present prior to the diagnosis ... high risk of such disorders. When three or more of ...
... Time for the Holiday ... ... 50%,of his yearly weight gain during the Holiday Season. That,s not good ... http://www.metabothin.net ), the herbal weight loss formula,from American Generic Laboratories, specifically designed ...
... Margolin Named President of Blue Cross of California, ... today announced that Brian A. Sassi has been ... Consumer Business Unit, which,includes the Individual, Senior and ... of Blue Cross of California, replaces Joan,Herman, who ...
... on Ice Skating Admission Through ... the End of the Season, PHILADELPHIA, ... and head outdoors this weekend for the,Healthy Kids Fest at the Blue ... for families to enjoy the winter,months, the skating season is in full ...
... 9. 2008 -- Two Hebrew University of Jerusalem researchers, ... awarded the 2008 Wolf Prize in Medicine for their ... cancer research. , Minister of Education Prof. Yuli ... the $100,000 prize, often referred to as Israels Nobel ...
Cached Medicine News:Health News:5 Factors Help Predict Psychosis in Children 2Health News:5 Factors Help Predict Psychosis in Children 3Health News:Metabothin B56 with Ephedra Extract Now Available 2Health News:WellPoint Appoints Brian A. Sassi as President and CEO of the Company's Consumer Business Unit 2Health News:WellPoint Appoints Brian A. Sassi as President and CEO of the Company's Consumer Business Unit 3Health News:Families Encouraged to Enjoy Healthy Kids Fest January 12 at the Blue Cross RiverRink 2Health News:Families Encouraged to Enjoy Healthy Kids Fest January 12 at the Blue Cross RiverRink 3Health News:2 Hebrew University scientists awarded Wolf Prizes 2
Stainless steel lancet blade in stainless steel....
In Stainless steel. Available in 1.5, 2.0,3.0 & 3.5 MM...
AXIOM Multistar is a ceiling-mounted single plane C-Arm system for universal angiography, diagnostics and intervention...
... supports the cardiac workflow through Xper: a ... personalized user settings. In addition Xper integrates ... user interface. For example the interventional tools ... controlled from tableside.,The excellent image quality and ...
Medicine Products: